Following the failure of two pivotal studies, Alkermes is unlikely to keep ALKS 5461 alive and must instead redefine its strategy, says Datamonitor Healthcare lead analyst Daniel Chancellor.
Alkermes announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461 (buprenorphine/samidorphan), last week,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?